Citigroup analysts say Sanofi’s best-selling drug Dupixent could face
competition in coming years from AstraZeneca’s tozorakimab, Pfizer’s tilrekimig
and AbbVie/Apogee’s zumilokibart. Dupixent (developed with Regeneron) drove
Sanofi’s third-quarter beat. Citigroup forecasts Dupixent sales growth slowing
from an estimated 32% this year to 12% in 2027, and warns Dupixent’s pricing
advantage may no longer support growth after 2027. Citigroup raises Sanofi PT to
€93 from €78.
